amicusrx.comAmicus Therapeutics | Advancing Therapies to Treat Rare Diseases

Contact Us Global Australia Canada France Germany Italy Japan Netherlands Spain Switzerland United Kingdom About Amicus Belief Statement Board of Directors Our Founding Legacy Senior Management Team Message from the President and CEO Patient Advocacy Expanded Access Patient Advisory Boards Rare Stories Resources Programs & Pipeline Our Pipeline Fabry Disease Pompe Disease Batten Disease Additional Preclinical Programs Clinical Trials Global Research Center Products Galafold ® (migalastat) Pombiliti ™ + Opfolda ™ (cipaglucosidase alfa-atga) (miglustat) AMICUS ASSIST ® Responsibility Ethics & Compliance Global Medical Affairs Corporate Giving Healing Beyond Disease ESG Report Investors & Media Investor Relations Corporate Governance Press Releases Events & Presentations Annual Reports & Proxies SEC Filings Stock Performance Investor FAQs Contact Us Sign Up for Email Alerts Careers Overview Who We Are Search Read more about Amicus Therapeutics A R re Story We Believe In Our Future. Read more about Pompe Disease Noah, 10 Living with Pompe Disease Read story A R re Journey Our Families are Part of the Amicus Experience. Megan, 24 Living with Pompe Disease A R re Commitment To Ensuring Patient Access to Medicines. Read more about our Expanded Access Program Michael, 25 Living with Fabry Disease About Amicus We are a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare diseases . News & Announcements Executive Chairman, John F. Crowley Delivers Notre Dame Commencement Address. March 5, 2020 Amicus Opens New Global Research and Gene Therapy Center of Excellence in Philadelphia March 2, 2020 Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates February 26, 2020 Amicus Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference February 19, 2020 Amicus Therapeutics to Announce Full-Year 2019 Financial Results on March 2, 2020 More ❯ Amicus Named a Great Place to Work-Certified™ Company in 2020 We take pride in the talented individuals that make up our organization and work hard to foster their growth. ❯ Learn MoreChairman & CEO John F. Crowley Featured on CNBC ❯ See clip here To Our Patient Community Partners: First and foremost, your safety and welfare and that of your families always has been and continues to be our number one priority. This is especially true in view of the global COVID-19 outbreak. Amicus remains committed to open and frequent communications to address any questions. We are in this fight together. We will maintain consistent monitoring of this unprecedented situation, provide updates of any changes and remain available to you. ❯ Resources and more information by programOfficial PROPEL study website. Now live!Programs & Pipeline We are leveraging our innovative technology platforms to develop treatments for human genetic diseases. More Rare Stories Be inspired by people living with rare disease across the globe. More Career @ Amicus Join a team committed to changing the lives of patients with rare metabolic diseases. Now hiring in multiple locations. More About Amicus Belief Statement Board of Directors Our Founding Legacy Senior Management Team Message from the President and CEO Patient Advocacy Disease Information Rare Stories Patient Advisory Boards Corporate Giving Resources Expanded Access Programs & Pipeline Pipeline Our Programs Clinical Trials Our Products Overview Amicus Assist™ Responsibility Ethics & Compliance Global Medical Affairs Corporate Giving Healing Beyond Disease ESG Report Investors & Media Corporate Governance Press Releases Events & Presentations Annual Reports & Proxies SEC Filings Stock Performance Investor FAQs Careers Overview Who We Are Search Social Media Twitter YouTube LinkedIn Copyright © 2022 Amicus Therapeutics, Inc. All rights reserved. NP-AT-ALL-00011119 Cookies Statement Terms of Use Privacy Notice Privacy Policy The site you are about to enter is intended for US healthcare professionals. Please confirm you are a US healthcare professional. I am a US healthcare professional I am not a US healthcare...